Trial Bank
3,129 trials match
Observational studies (…) are hidden. Tick 'Include observational studies' to show them.
- SPRING: Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
MSRelapsing MSPhase 4Running, not recruiting
fingolimod · Novartis Pharmaceuticals · 2020 · 14 participants
- NMOSD: Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD
NMOSDNot a drug-phase studyRecruiting
Icahn School of Medicine at Mount Sinai · 2025 · 20 participants
- MS-FLOWER: MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience
MSMS (type not specified)Not a drug-phase studyCompleted
Ad scientiam · 2025 · 62 participants
- HOBSCOTCH-MS-Efficacy Trial
MSProgressive MSNot a drug-phase studyRecruiting
Dartmouth-Hitchcock Medical Center · 2025 · 125 participants
- Understanding and Enhancing Human Health and Movement
MSMS (type not specified)Not a drug-phase studyRecruiting
Louis Stokes VA Medical Center · 2021 · 75 participants
- LTS18002: A study to investigate long-term safety and tolerability of frexalimab in participants with multiple sclerosis
MSRelapsing MSPhase 3Not yet recruiting
frexalimab · Sanofi-Aventis Recherche & Developpement · 2027 · 37 participants
- TG1101-RMS303: An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
MSRelapsing MSPhase 3Running, not recruiting
ublituximab · TG Therapeutics, Inc. · 2019 · 1,100 participants
- OSSIA: A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
MSRelapsing and progressivePhase 4Recruiting
Genentech, Inc. · 2026 · 100 participants
- A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
MSProgressive MSPhase 2Recruiting
Sundance Biosciences, Inc. · 2026 · 20 participants
- TG1101-RMS-PED304: Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
MSRelapsing MSPhase 2Phase 3Recruiting
fingolimod, ublituximab · TG Therapeutics, Inc. · 2026 · 240 participants
- TG1101-RMS-SC201: A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
MSNMOSDRelapsing MSPhase 2Recruiting
ublituximab · TG Therapeutics, Inc. · 2026 · 350 participants
- Dry Needling in Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyRecruiting
University of South Florida · 2026 · 24 participants
- sSIT-MS: Short Sprint Interval Training in People With Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyCompleted
Universidad de León · 2026 · 40 participants
- A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS
MSMS (type not specified)Phase 1Phase 2Suspended
Assistance Publique Hopitaux De Paris · 2024 · 80 participants
- OLERO: A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
MSRelapsing and progressivePhase 3Running, not recruiting
ocrelizumab · Hoffmann-La Roche · 2022 · 1,300 participants
- PET-AON: Efgartigimod for the Treatment of Acute Optic Neuritis
Optic neuritisPhase 2Recruiting
efgartigimod alfa · Anastasia Vishnevetsky, MD, MPH · 2025 · 20 participants
- OleroMAX: An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
MSMS (type not specified)Phase 3Recruiting
ocrelizumab · Hoffmann-La Roche · 2024 · 500 participants
- NeuroDIP: Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health
MOGADMSNMOSDNot a drug-phase studyNot yet recruiting
Institut National de la Santé Et de la Recherche Médicale, France · 2026 · 500 participants
- cosMOG: A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
MOGADPhase 3Running, not recruiting
rozanolixizumab · UCB Biopharma SRL · 2022 · 113 participants
- FEMINISEP: Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group
MSMS (type not specified)Not a drug-phase studyRecruiting
University Hospital, Bordeaux · 2023 · 160 participants
- A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
MSNMOSDRelapsing and progressivePhase 1Recruiting
azercabtagene zapreleucel · TG Therapeutics, Inc. · 2025 · 100 participants
- MSS: A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
MSMS (type not specified)Phase 2Recruiting
Celgene · 2025 · 200 participants
- Effect of a Mobile Health App on Pain and Quality of Life in Patients With Neuropathic Pain in Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyCompleted
Meryem Kocaslan Toran · 2025 · 56 participants
- ZB020-03-001: A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 3Recruiting
orelabrutinib · Zenas BioPharma (USA), LLC · 2026 · 705 participants
- ZB020-03-002: A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
MSRelapsing and progressivePhase 3Recruiting
orelabrutinib · Zenas BioPharma (USA), LLC · 2026 · 990 participants
- Tai Chi Training for Persons With Multiple Sclerosis.
MSRelapsing MSNot a drug-phase studyRunning, not recruiting
Karolinska Institutet · 2025 · 35 participants
- EXO-MS: Evaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyNot yet recruiting
Otto Bock Healthcare Products GmbH · 2026 · 100 participants
- Evaluation of the Effect of Mental Imagery Training Combined With Modified Constraint-Induced Movement Therapy in Individuals With Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyNot yet recruiting
Hacettepe University · 2026 · 14 participants
- T4MS: Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
MSEarly (CIS/RIS)Not a drug-phase studyRecruiting
University Hospital, Bordeaux · 2021 · 150 participants
- CLOU064C12306: Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
MSRelapsing MSPhase 3Recruiting
remibrutinib · Novartis Pharmaceuticals · 2025 · 400 participants
- The Effects of Synchronous and Asynchronous Pilates Training Based on Telerehabilitation on Core Stabilization, Balance, Cognitive Functions, and Quality of Life in Individuals With Multiple Sclerosis: A Single-Blind Randomized Controlled Trial
MSMS (type not specified)Not a drug-phase studyRecruiting
Yuzuncu Yil University · 2026 · 38 participants
- Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy.
Optic neuritisNot a drug-phase studyTerminated
Medical University of Bialystok · 2020 · 7 participants
- Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in Multiple Sclerosis
MSRelapsing MSNot a drug-phase studyRunning, not recruiting
Chinese University of Hong Kong · 2023 · 50 participants
- ENHANCE: Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
MSRelapsing MSPhase 3Recruiting
ublituximab · TG Therapeutics, Inc. · 2023 · 800 participants
- DIIVA-MS: Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
MSProgressive MSNot a drug-phase studyRecruiting
Emory University · 2025 · 138 participants
- TG1101-RMS-SC301: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
MSRelapsing MSPhase 3Running, not recruiting
ublituximab · TG Therapeutics, Inc. · 2025 · 360 participants
- SPIN: Efficacy of Seated Physical Activity INtervention(SPIN) for Wheelchair Users With Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyNot yet recruiting
The University of Texas Health Science Center, Houston · 2027 · 100 participants
- CeV: Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis
MSMS (type not specified)Not a drug-phase studyRecruiting
Clinique Neuro-Outaouais · 2025 · 70 participants
- VR-GSS: Virtual Reality - Gamma Sensory Stimulation for Improving Fatigue in People With Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyRecruiting
Clarity Health Technologies, Inc · 2026 · 30 participants
- HiHat: The HIt HArd and hiT Early in Multiple Sclerosis Trial
MSRelapsing MSPhase 2Recruiting
cladribine, rituximab · Uppsala University · 2026 · 60 participants
- O-MEG-A-MIND: OPM- MEG in Non-immune And iMmune-medIated Neurological Disease
ADEMMSNot a drug-phase studyRecruiting
Aston University · 2026 · 90 participants
- CRSP-AID-502: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
MOGADMSNMOSDProgressive MSPhase 1Phase 2Not yet recruiting
CRISPR Therapeutics · 2026 · 220 participants
- Motor Imagery and Action Observation for Gait Function in MS
MSMS (type not specified)Not a drug-phase studyRecruiting
Hacettepe University · 2026 · 20 participants
- Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
MSProgressive MSPhase 1Phase 2Recruiting
cilostazol, dantrolene, leucovorin +2 · National Institute of Allergy and Infectious Diseases (NIAID) · 2017 · 250 participants
- BEAT-MS: Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
MSRelapsing and progressivePhase 3Recruiting
National Institute of Allergy and Infectious Diseases (NIAID) · 2020 · 156 participants
- Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for MS
MSMS (type not specified)Phase 1Recruiting
The Foundation for Orthopaedics and Regenerative Medicine · 2021 · 15 participants
- Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain
MSMS (type not specified)Not a drug-phase studyRunning, not recruiting
Shirley Ryan AbilityLab · 2025 · 15 participants
- Objective Longitudinal Monitoring of Postural Stability and Gait During Neurorehabilitation: Clinical Application of Instrumented Posturography and Three-Dimensional Motion Analysis
MSMS (type not specified)Not a drug-phase studyEnrolling by invitation
Somogy Megyei Kaposi Mór Teaching Hospital · 2026 · 151 participants
- CAMINA: Efficacy and safety of cromoglycate as a new symptomatic treatment in patients with multiple sclerosis
MSMS (type not specified)Phase 2Running, not recruiting
cromolyn · Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos · 2024 · 120 participants
- STEMS2: Foetal neural stem cells transplantation in progressive multiple sclerosis
MSProgressive MSPhase 2Recruiting
tacrolimus anhydrous · Ospedale San Raffaele S.r.l. · 2025 · 86 participants
About this data
Where the data comes from
ClinicalTrials.gov, the EU Clinical Trials Register, ISRCTN, ChEMBL and Europe PMC, combined into the MSFrontier trial bank.
How it is collected
Registry records are collected automatically, duplicate records across registries are merged, and treatments, phases and populations are tagged by software from the registry data. When an error is reported, we fix the rule so the fix applies to every trial, and log it in the Corrections log.
Last update
Trial bank updated recently. Sources and corrections
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error